Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma.

Next Previous
X
Search
Trial Profile

A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma.

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TPI 287 (Primary) ; Irinotecan; Temozolomide
  • Indications Neuroblastoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 19 Jan 2016 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 17 Nov 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 16 Apr 2012 Planned end date changed from 1 Dec 2014 to 1 Dec 2018 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top